개 아토피 피부염 시장 보고서 : 약제 클래스별, 투여 경로별, 유통 채널별, 지역별(2025-2033년)

The global canine atopic dermatitis market size reached USD 2.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 7.7 Billion by 2033, exhibiting a growth rate (CAGR) of 13.1% during 2025-2033.

Canine atopic dermatitis (CAD) is an allergic skin disease in dogs caused by allergens, such as pollens, house dust, insect bites, grass and food ingredients. It is an inherited predisposition that generally affects dogs aged between six months to three years. It commonly affects the ventral abdomen, mouth, eyes, interdigital skin, ear pinnae, carpal, elbow and perineal area of the animals. CAD is characterized by various symptoms, such as excessive scratching, inflammation and itching around paws, underarms and face. It can be treated by immuno-suppressants, monoclonal anatomy and glucocorticoids. They can be administered through oral, injectables and topical medications. It is known to be highly prevalent in German shepherds, Labradors, golden retrievers and pugs.

Canine Atopic Dermatitis Market Trends:

The increasing occurrence of CAD in domesticated dogs across the globe is one of the key factors creating a positive outlook for the market. This can be attributed to the changing environmental conditions, rising air pollution levels and prolonged exposure to allergens. Moreover, the increasing concerns and rising awareness among pet owners regarding early symptoms and signs of CAD, such as redness, greasy skin and yeasty smell, are providing a thrust to the market growth. Additionally, the widespread adoption of monoclonal antibodies for the treatment of the disease is favoring the market growth. These antibodies aid in directing the required immune response and calming the spread of the disease. In line with this, the increasing number of veterinary practitioners, hospitals and clinics dedicated to providing improved care for animals is positively impacting the market growth. Other factors, including the implementation of various government initiatives to restrict the usage of off-label human drugs on animals, along with extensive research and development (R&D) in the field of veterinary sciences, are anticipated to drive the market toward growth.

Key Market Segmentation:

Breakup by Drug Class Type:

• Glucocorticoids
• Immunosuppressants
• Monoclonal Antibody
• Others

Breakup by Route of Administration:

• Topical
• Oral
• Injectable

Breakup by Distribution Channel:

• Veterinary Hospitals
• Pet Clinics
• Pharmacies and Drugstores
• Others

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being AB Science, Bimeda Inc., Bioceltix SA, Boehringer Ingelheim International GmbH, Ceva Sante Animale, Dechra Pharmaceuticals PLC, Elanco Animal Health Incorporated, Phibro Animal Health Corporation, Toray Industries Inc., Vetoquinol S.A., Virbac and Zoetis Inc.

Key Questions Answered in This Report:

• How has the global canine atopic dermatitis market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global canine atopic dermatitis market?
• What are the key regional markets?
• What is the breakup of the market based on the drug class type?
• What is the breakup of the market based on the route of administration?
• What is the breakup of the market based on the distribution channel?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global canine atopic dermatitis market and who are the key players?
• What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Canine Atopic Dermatitis Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Drug Class Type

• 6.1 Glucocorticoids
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Immunosuppressants
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Monoclonal Antibody
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Others
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Route of Administration

• 7.1 Topical
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Oral
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Injectable
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Distribution Channel

• 8.1 Veterinary Hospitals
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Pet Clinics
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Pharmacies and Drugstores
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Others
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 AB Science
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
  • 14.3.2 Bimeda Inc.
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
  • 14.3.3 Bioceltix SA
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
  • 14.3.4 Boehringer Ingelheim International GmbH
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
  • 14.3.5 Ceva Sante Animale
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
  • 14.3.6 Dechra Pharmaceuticals PLC
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
  • 14.3.7 Elanco Animal Health Incorporated
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
  • 14.3.8 Phibro Animal Health Corporation
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Toray Industries Inc.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 Vetoquinol S.A.
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
  • 14.3.11 Virbac
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
    • 14.3.11.3 Financials
    • 14.3.11.4 SWOT Analysis
  • 14.3.12 Zoetis Inc.
    • 14.3.12.1 Company Overview
    • 14.3.12.2 Product Portfolio
    • 14.3.12.3 Financials
    • 14.3.12.4 SWOT Analysis